Immunotoxin treatment of cancer

被引：302

作者：

Pastan, Ira ^{[1
]}

Hassan, Raffit ^{[1
]}

FitzGerald, David J. ^{[1
]}

Kreitman, Robert J. ^{[1
]}

机构：

[1] NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2007年 / 58卷

关键词：

Pseudomonas toxin; diphtheria toxin; monoclonal antibody; recombinant immunotoxin;

D O I：

10.1146/annurev.med.58.070605.115320

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Immunotoxms are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.

引用

页码：221 / 237

页数：21

共 101 条

[1] A urokinase-activated recombinant diphtheria toxin targeting the granulocyt-emacrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts [J].

Abi-Habib, RJ ;

Liu, SH ;

Bugge, TH ;

Leppla, SH ;

Frankel, AE .

BLOOD, 2004, 104 (07) :2143-2148

[2]

AMLOT PL, 1993, BLOOD, V82, P2624

[3] Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2 [J].

Attia, P ;

Powell, DJ ;

Maker, AV ;

Kreitman, RJ ;

Pastan, I ;

Rosenberg, SA .

JOURNAL OF IMMUNOTHERAPY, 2006, 29 (02) :208-214

[4] Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2 [J].

Azemar, M ;

Djahansouzi, S ;

Jäger, E ;

Solbach, C ;

Schmidt, M ;

Maurer, AB ;

Mross, K ;

Unger, C ;

von Minckwitz, G ;

Dall, P ;

Groner, B ;

Wels, WS .

BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 (03) :155-164

[5] INTERLEUKIN-2 RECEPTOR TARGETED CYTO-TOXICITY INTERLEUKIN-2 RECEPTOR MEDIATED ACTION OF A DIPHTHERIA-TOXIN RELATED INTERLEUKIN-2 FUSION PROTEIN [J].

BACHA, P ;

WILLIAMS, DP ;

WATERS, C ;

WILLIAMS, JM ;

MURPHY, JR ;

STROM, TB .

JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (02) :612-622

[6] PHARMACOKINETICS OF THE RECOMBINANT FUSION PROTEIN DAB486IL-2 IN ANIMAL-MODELS [J].

BACHA, P ;

FORTE, S ;

KASSAM, N ;

THOMAS, J ;

AKIYOSHI, D ;

WATERS, C ;

NICHOLS, J ;

ROSENBLUM, M .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (06) :409-414

[7]

Barth S, 2000, BLOOD, V95, P3909

[8] IDENTIFICATION OF RESIDUES THAT STABILIZE THE SINGLE-CHAIN FV OF MONOCLONAL-ANTIBODIES B3 [J].

BENHAR, I ;

PASTAN, I .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23373-23380

[9] Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine - A report of three cases [J].

BlasinskaMorawiec, M ;

Robak, T ;

Krykowski, E ;

Hellmann, A ;

UrbanskaRys, H .

LEUKEMIA & LYMPHOMA, 1997, 25 (3-4) :381-385

[10]

BOLOGNESI A, 1992, CLIN EXP IMMUNOL, V89, P341

← 1 2 3 4 5 6 7 8 9 10 →